Table 3.
The HR of invasive breast cancer associated with different type of HT prescription and different duration of use in 2004–2005
| Prescription in DDD | Estrogen and progesterone combinations | Systemic estrogens | Tibolone | Vaginal estrogens | ||||
|---|---|---|---|---|---|---|---|---|
| Number | HR | Number | HR | Number | HR | Number | HR | |
| 0 | 3584 | 1 | 4398 | 1 | 4390 | 1 | 4265 | 1 |
| 1–180 | 134 | 1.07 (0.90–1.27 | 41 | 0.86 (0.63–1.17) | 66 | 1.32 (1.03–1.68) | 290 | 0.84 (0.74–0.95) |
| 181–365 | 135 | 1.24 (1.04–1.47) | 52 | 1.12 (0.85–1.48) | 41 | 1.16 (0.85–1.60) | 35 | 0.93 (0.66–1.30) |
| >365 | 744 | 2.06 (1.90–2.24) | 106 | 1.03 (0.85–1.25) | 100 | 1.23 (1.01–1.51) | 7 | 0.65 (0.31–1.37) |
All values are adjusted for age, number of child births, whether or not the women attended the screening program in 2004–2009 and whether or not a nonuser in 2004–2005 started with HT use in 2006–2009.